Help employers find you! Check out all the
COLORADO SPRINGS, Colo., July 29, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds the Editorial Board of the New York Times for taking a strong position in opposition to current federal law on cannabis in its Sunday, July 27, 2014 publication. The New York Times also announces a series of upcoming editorials and articles this week exploring the issue called "High Time: An Editorial Series on Marijuana Legalization".
"The federal government should repeal the ban on marijuana.... We reached that conclusion after a great deal of discussion among the members of The Times's Editorial Board, inspired by a rapidly growing movement among the states to reform marijuana laws," stated the New York Times Editorial Board's sweeping statement.
"As perhaps the most respected newspaper in the United States, it is more than noteworthy that the editorial board of the New York Times has taken such a strong stance on cannabis legalization, relying in part on the evidence of the success of medical benefits," said Chad S. Johnson, Director, COO and General Counsel, Cannabis Science, Inc. "As a bell weather of the view of American citizens, the New York Times' action is yet another example of prestigious, mainstream journalistic institution like CNN and Dr. Sanjay Gupta in openly challenging the irrational federal classification of cannabis."
Also this weekend, the New York Times ran the first editorial and article in its "High Time" series: "Let States Decide on Marijuana" by David Firestone and "The Public Lightens Up About Weed" by Juliet Lapidos.
At High Time: Repeal Prohibition, Again, you may view the full editorial board's statement and the additional editorial and article may be viewed through the following links: Let States Decide on Marijuana and The Public Lightens Up About Weed, respectively.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
Robert Kane, CFO & Director
Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
SOURCE Cannabis Science, Inc.